Identification of a novel circular RNA circZNF652/miR-486-5p/SERPINE1 signaling cascade that regulates cancer aggressiveness in glioblastoma (GBM)

Liang Liu\textsuperscript{a,b}, Shan Xiao\textsuperscript{b,e}, Yan Wang\textsuperscript{c}, Zifeng Zhu\textsuperscript{b}, Yiyao Cao\textsuperscript{a}, Sen Yang\textsuperscript{a}, Rongkang Mai\textsuperscript{a}, and Yong Zheng\textsuperscript{a}

\textsuperscript{a}Department of Neurosurgery, The Second Affiliated Hospital of Shenzhen University (People's Hospital of Shenzhen Baoan District), Shenzhen, Guang Dong, China; \textsuperscript{b}Department of Endocrinology, The Second Affiliated Hospital of Shenzhen University (People's Hospital of Shenzhen Baoan District), Shenzhen, Guang Dong, China; \textsuperscript{c}Department of General Practice Medicine, The Second Affiliated Hospital of Shenzhen University (People's Hospital of Shenzhen Baoan District), Shenzhen, Guang Dong, China

\textbf{ABSTRACT}

Circular RNAs (circRNAs) are closely associated with cancer development in glioblastoma (GBM), and this study aims to explore the molecular mechanisms of a novel circular RNA circZNF652 in regulating GBM aggressiveness. The present study found that CircZNF652 and SERPINE1 were upregulated, while miR-486-5p was downregulated in GBM tissues and cell lines, and GBM patients with high expression of CircZNF652 and SERPINE1, and patients with low expression of miR-486-5p tended to have a worse prognosis. Further results validated that both silencing of circZNF652 and miR-486-5p overexpression suppressed cell growth, migration, invasion, epithelial–mesenchymal transition (EMT) and tumorigenesis in GBM cells \textit{in vitro} and \textit{in vivo}. Next, the underlying mechanisms were investigated, and we found that circZNF652 sponged miR-486-5p to upregulate SERPINE1 in GBM cells. Also, we validated that knock-down of circZNF652 regulated the miR-486-5p/SERPINE1 axis to reverse the malignant phenotypes in GBM cells. Interestingly, we noticed that GBM cells derived exosomes were characterized by high-expressed CircZNF652. Collectively, we concluded that targeting the circular RNA circZNF652/miR-486-5p/SERPINE1 axis was a novel and effective strategy to suppress cancer progression in GBM.

\section*{Introduction}

Glioblastoma (GBM) is a serious brain tumor with high aggressiveness, which mostly occurs in adults between 55 and 60 years [1]. Despite the improvement of treatment strategy for GBM, the majority of GBM patients have poor prognosis as the results of its metastatic properties [2,3]. Besides, the greatest challenges of GBM treatment include tumor metastasis, recurrence, radio- and chemoresistance, and immune escape, etc. [4]. Therefore, identification of the novel diagnostic and therapeutic targets is urgent to improve the poor prognosis of GBM patients.

Circular RNAs (circRNAs) are conserved and closed RNA loops without gene coding potential [5–7]. Commonly, circRNAs regulate tumor progression through sponging miRNA to modulate the downstream gene expression. For example, circPVT1 accelerates the breast cancer development by sponging miR-29a-3p to promote HIF-1α expression [8]. Xu et al. [9] reported that hsa_circ_0001869 facilitates non-small cell lung cancer (NSCLC) progression through sponging miR-638 to enhance FOSL2 expression. Furthermore, emerging evidences demonstrate that circRNAs exhibits significant influences in GBM. For example, hsa_circ_0043278 sponges miR-638 to promote GBM multiforme through accelerating HOXA9 expression [10]. CircCDR1 suppresses GBM progression through disrupting p53/MDM2 complex [11]. CircZNF652 is a newly discovered circRNA, which is aberrantly overexpressed in hepatocellular carcinoma (HCC), and acts as an oncogene in HCC through promoting cell migration, invasion and EMT process [12]. However, the role and mechanism of circZNF652 in GBM remains unclear.

\section*{CONTACT}

Yong Zheng \textsuperscript{a}\ email: szy3569@126.com Department of Neurosurgery, The Second Affiliated Hospital of Shenzhen University (People's Hospital of Shenzhen Baoan District), Longjing Second Road No. 118, Shenzhen, Guang Dong 518101, China

\textsuperscript{e}Co-first authors.

Supplemental data for this article can be accessed \textit{here}

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MicroRNAs (miRNAs) are conserved group of small non-coding RNAs that regulate multiple physiological and pathological processes by negatively modulating gene transcriptional and post-transcriptional expression [13]. The main modulating pattern is that miRNAs directly target the 3'-untranslated region (3'-UTR) of target genes for their degradation and inhibition [14]. Interestingly, evidences suggest that miRNAs play the critical roles in tumorigenesis, development and progression in GBM. For example, Wang et al. [15] report that miR-16 suppressed glioblastoma growth by directly interacting cyclin D1 and WIP1 in vitro and in vivo, and miR-623 acts as a tumor suppressor to inhibit EMT process via targeting TRIM44 in GBM [16]. Salimian et al. [17] report that miR-486-5p acts as a tumor suppressor in bladder cancer through enhancing cells sensitive to cisplatin. Among all the tumor-associated miRNAs, miR-486-5p was significantly upregulated in cervical cancer [18]. However, the role of miR-486-5p in regulating GBM pathogenesis had not been investigated.

Therefore, in this study, we aimed to explore the involvement of the circZNF652/miR-486-5p/ SERPINE1 axis in regulating cancer aggressiveness in GBM, and uncover the potential underlying mechanisms. We expectedly identified that circZNF652 accelerated GBM aggressiveness by upregulating SERPINE1 through sponging miR-486-5p. Hence, our findings might provide a novel therapeutic target and signaling pathway for GBM treatment.

Materials and methods

Clinical samples

A total 52 pairs of GBM tumorous and adjacent non-tumorous tissues were obtained from the patients at The Second Affiliated Hospital of Shenzhen University (People’s Hospital of Shenzhen Baoan District). All patients have signed informed consent, and this study was approved by The Ethics Committee of The Second Affiliated Hospital of Shenzhen University (People's Hospital of Shenzhen Baoan District), and the approval number was 2020120813. The specimens were moved by surgical techniques, then immediately snap-frozen in liquid nitrogen and stored at −80°C.

Cell lines and cell cultures

The normal human astrocyte (NHA) and human GBM cell lines A172, U251, LN229, and U87 were purchased from American Type Culture Collection (ATCC, VA, USA) and Chinese Academy of Sciences (Shanghai, China). All cells were incubated in DMEM medium (#10566016, Invitrogen, CA, USA) and supplemented with 10% fetal bovine serum (FBS) (#10100139 C, Hyclone, UT, USA) and 1% penicillin and streptomycin (#10378016, Invitrogen, Carlsbad, CA, USA) in an incubator with 5% CO2 at 37°C.

Cell transfection

A172 cells and U87 cells were transfected with pcDNA3.1 plasmid or small interfering RNAs (siRNAs) using Lipofectamine 2000 (#11668019, Invitrogen, CA, USA). Si-NC, Si-circZNF652 (5’-AAC ACA CAC TGC ACA CAC AAA-3’), NC mimic, miR-486-5p mimic (5’-UGC UGU ACU GAG CUG CCC CGA G-3’), NC inhibitor, miR-486-5p inhibitor (5’-CUC GGG GCA GCU CAG UACCAG A-3’) were designed and synthesized from GenePharma (Shanghai, China).

Ribonuclease (RNase) R and actinomycin D digestion

For RNase R digestion analyses, total RNA was incubated with 3 U/μg RNase R (#11119915001, Sigma-Aldrich, MO, USA) at 37°C for 30 min. Then, the mRNA levels of circZNF652 and linear ZNF652 were measurement by qRT-PCR. Similarly, total RNA was incubated with 2 mg/mL actinomycin D (R & D Systems, Shanghai, China) for 4, 8, 18, 24 h. And the mRNA levels of circZNF652 and linear ZNF652 were measurement by RT-qPCR.

RNA isolation and RT-qPCR

Total RNA was extracted from cells and tissues using Trizol reagent (#15596018, Life Technologies, CA, USA) according to the
manufacturer’s instruction. cDNA was generated using TaqMan MicroRNA Reverse Transcription kit (#4366596, Applied Biosystem, CA, USA) and amplified using Power SYBR®-Green PCR Master mix (#4367659, Thermo Fisher Scientific, MA, USA) following the manufacturer’s instruction. The primers were listed as following: CircZNF652 forward, 5’-GGG CAC AAA CAG TTC ATG TG-3’, reverse, 5’-TGC GTT TGA ATG ATT TTC CA-3’. ZNF652 forward, 5’- CAC AAT GTG GCA GGA GAC AGA-3’, reverse, 5’-TCA TGG AGA TGC GGT TTG CT-3’. MiR-486-5p, forward, 5’-CGC TTC CTG TAC TGA GCT GC-3’, reverse, 5’-ATC CAG TGC AGG GTC CGA GG-3’. SERPINE1 forward, 5’-CTT CCA GCA GCT GAA TTC TT-3’, reverse, 5’-GGG TTT CTC CTC CTG AAG TTC T-3’. GAPDH forward, 5’-GTT CAC CAG GGC TGC TTT TA-3’, reverse, 5’-CCC GTT CTC AGC CAT GTA GT-3’. U6 forward, 5’-CTC GCT TCG GCA GCA CA-3’, reverse, 5’-AAC GCT TCA CGA ATT TGC GT-3’. Relative expression was quantified by the $2^{-\Delta\Delta Ct}$ methods. Moreover, the nuclear and cytoplasmic RNA of cells were isolated using Cytoplasmic & Nuclear RNA Purification Kit (Norgen Biotek, Thorold, Canada) according to the manufacturer’s protocol. GAPDH was used as a control for cytoplasmic transcript and U6 was used as a control for nuclear transcript.

**Western blotting assay**

Total protein of cells or tissues was extracted using RIPA lysis buffer (#P0013K, Beyotime, Shanghai, China) following the manufacturer’s protocol. Then, protein was separated by electrophoresis on a 10% SDS-PAGE gel, and transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% nonfat milk and incubated with primary antibodies including lamin B (ab32535), α-tublin (ab7291), E-cadherin (ab76055), N-cadherin (ab76011), vimentin (ab92547), SERPINE1 (ab222-754), GAPDH (ab8245) overnight. And then incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. All antibodies were purchased from Abcam (MA, USA).

**Cell counting kit-8 (CCK-8) assay**

Cells were seeded onto 96-well plates at density 5000 cells per well. Then, the cell activity was determined using Cell Counting Kit-8 (#C0039, Beyotime, Shanghai, China) following manufacturer’s protocol. And the optical density was calculated at 450 nm.

**Colonies formation assay**

Cells were seeded onto 6-well plates at density 5000 cells per well. Cells were incubated in an incubator with 5% CO$_2$ at 37°C for 14 days, the medium was changed every 3 days. Then, cells were fixed with methanol and incubated with 0.1% crystal violet at room temperature for 15 min. More than 50 cells were considered a colony, the number of colonies were counted and imaged under a microscope (Leica, Wetzlar, Germany).

**Wound healing assay**

Cells were plated onto 24 well-plates at density $1 \times 10^5$ cells per well and incubated at an incubator with 5% CO$_2$ at 37°C overnight. Then, a wound was generated on the cell monolayer using a 200 µL pipette tip. And the trail of migratory cells was photographed at 0 and 24 h.

**Transwell assay**

Invasion of cells were measured using transwell assay with 8 µm pore size (Millipore, USA) insert. The membrane of upper chamber was coated with Matrigel for 30 min before the 2 × $10^4$ cells were seed into the upper chamber. Besides, the DMEM medium with 20% FBS were added into the lower chamber. The transwell was incubated at an incubator with 5% CO$_2$ at 37°C for 24 h. The cells at the front filter were removed using sterile swabs. And the invaded cells at opposite were stained with 0.1% crystal violet at room temperature for 15 min. The number of invaded cells were counted and photographed at an inverted microscope (Leica, Wetzlar, Germany).

**Dual-luciferase reporter assay**

The region of circZNF652 or SERPINE1 gene sequences containing the binding sites with miR-
486-5p was cloned into the pGL3 luciferase reporter plasmid. For investigate the target relationship between circZNF652 or SERPINE1 and miR-486-5p., the mutant circZNF652 or SERPINE1 gene sequences was cloned into the pGL3 luciferase reporter plasmid. Then, the plasmids were transfected into 293 T cells using Lipofectamine 2000 (Invitrogen, Thermo-Fisher Scientific). After 48 h, the luciferase activity was detected using a dual-luciferase reporter gene assay kit (Beyotime, Shanghai, China) according to the manufacturer’s protocol.

RNA immunoprecipitation (RIP) assay

RIP assay was performed using a Magna RIP™ RNA-Binding Protein Immunoprecipitation kit (Millipore, Billerica, MA, USA). Briefly, cells were treated with 1% formaldehyde and then lysed in RIPA buffer supplemented with recombinant RNase inhibitor (Takara, Dalian, China) and Protease inhibitor cocktail (Millipore, MA, USA). Furthermore, cell lysates were incubated with Argonaute-2 (Ago2) antibody or Immunoglobulin G (IgG) antibody. And the Sepharose beads (BioRad, CA, USA) were added into the mixtures. And the expression of circZNF652 and miR-486-5p was measured by qRT-PCR.

Xenograft tumor mice

A total 16 four-week old male BALB/C nude mice were randomly divided into two groups, including si-NC group and si-circZNF652 group. circZNF652-silenced A172 cells were subcutaneously injected into the back of mice. The size of tumors was measured every 7 days for 28 days. The size of tumor volume = (length x width [2])/2. After 28 days, mice were sacrificed and tumors were separated for subsequent experiments. All animal experiments in this study were approved by the Ethics Committee of The Second Affiliated Hospital of Shenzhen University (People’s Hospital of Shenzhen Baoan District).

Immunohistochemical (IHC) staining assay

Frozen tissue sections were treated with a hydrogen peroxide solution at room temperature for 1 h. And then sections were incubated with primary Ki67 antibody at room temperature for 2 h. After washed and incubated with secondary antibody labeled with horseradish peroxidase at room temperature for 30 min. And the positive Ki67 cells were observed and imaged under an invert microscope.

Statistical analysis

GraphPad Primer 7 was used to perform statistical analysis in this study. Data were presented as mean ± SD. Comparisons the differential significance between groups was performed by Student’s t-test or one-way ANOVA. Besides, the correlations between circZNF652, miR-486-5p, and SERPINE1 were accomplished by Spearman correlation. P value <0.05 was considered as statistical significance.

Results

Upregulation of circ-ZNF652 in GBM tissues and cell lines, and associated with aggravate progression in GBM

To investigate whether dysregulated circ-ZNF652 affected GBM progression, the expression of circ-ZNF652 in GBM tissues and adjacent normal tissues was detected. We found upregulation of circ-ZNF652 in GBM tissues compared to adjacent normal tissues (Figure 1(a)). Moreover, we found expression of circ-ZNF652 was increased in advanced clinical stage than early clinical stage in glioma (Figure 1(b)). According to the median expression of circZNF652, GBM patients were separated into high expression of circZNF652 group and low-expression circZNF652 group, and the survival curve showed high expression of circZNF652 with poor survival time (Figure 1(c)). In addition, we analyzed the expression of circZNF652 in GBM cell lines and NHAs, the results exhibited high expression of circZNF652 in GBM cell lines than NHAs (Figure 1(d)). These finding suggested that upregulation of circZNF652 was associated with poor prognosis of GBM patients.

Stability and cellular localization of circZNF652 in GBM cells

We further to test the stability and characteristics of circular RNA circZNF652. The stability of
circZNF652 was determined by RNase R and actinomycin D, the results showed that RNase R significantly inhibited expression of linear ZNF652, while had no obviously effects on expression of circZNF652 (Figure 2(a,b)). Besides, the results of actinomycin D treatment revealed stability of circZNF652 compared to linear ZNF652 in GBM cells (Figure 2(c,d)). Furthermore, we detected the distribution of circZNF652 in nucleus and cytoplasm of GBM cells. As shown in Figure 2(e-k), circZNF652 was mainly distributed in the cytoplasm of GBM cells. Taken together, the circular structure of circZNF652 was stable and mainly distributed in the cytoplasm of GBM cells. In addition, the GBM cells-derived exosomes were isolated, and our data in Figure S1 suggested that those exosomes contained high-volume of circZNF652. However, the detailed mechanisms that circZNF652-containing exosomes regulated GBM progression were still needed to be uncovered in our future work.

**Knockdown of circZNF652 suppressed GBM cell growth, migration, invasion, and EMT process**

We further determined the effects of circZNF652 on GBM cells through lose-of-function experiments. The results showed that GBM cell proliferation ability and colony formation ability were depressed by silence of circZNF652 (Figure 3(a,
Besides, cell migration and invasion also inhibited by silence of circZNF652 (Figure 3(e-h)). Moreover, the effect of circZNF652 on epithelial–mesenchymal transition (EMT) was measured, Western blot results exhibited the epithelial cell marker E-cadherin was upregulated, and the mesenchymal cell markers N-cadherin and vimentin was downregulated by silence of circZNF652 (Figure 3(i-l)). Taken together, down-regulation of circZNF652 suppressed the cell growth, migration, invasion, and EMT process in GBM.

CircZNF652 functioned as a sponger for miR-486-5p in GBM cells

Then, we detected the potential mechanism of circZNF652 affected GBM cells, the miRNAs targeted with circZNF652 were predicated using StarBase (http://starbase.sysu.edu.cn/). The binding sequences of a candidate miR-486-5p with circZNF652 was showed in Figure 4(a). Dual-luciferase reporter assay was used to determine the interaction between miR-486-5p and circZNF652. As shown in Figure 4(b), the luciferase activity was suppressed by co-transfection of circZNF652-wt and miR-486-5p mimic into 293 T cells, but couldn’t affect the mutant one (Figure 4(b)). Furthermore, RIP assay was used to test interaction between miR-486-5p and circZNF652. The results showed that both circZNF652 and miR-486-5p were precipitated by anti-Ago2 compared to anti-IgG (Figure 4(c,d)). Next, we explored the function of miRNA-486-5p in GBM cells by inhibition of miR-486-5p expression. As shown in Figure 4(e), the expression of miR-486-5p was significantly reduced by miR-486-5p inhibitor. Then, we validated that circZNF652

![Figure 3](image-url). Knockdown of circZNF652 suppressed GBM cell growth, migration, invasion, and EMT process. (a) and (b) Cell viability was examined using CCK-8 assay after A172 and U87 cells were transferred with si-NC or si-circZNF652. (c) and (d) The colony formation number was measured using colony formation assay after A172 and U87 cells were transferred with si-NC or si-circZNF652. (e) and (h) Cell migration and invasion were determined using wound healing assay and transwell assay after A172 and U87 cells were transferred with si-NC or si-circZNF652. (i)-(l) The protein level of E-cadherin, N-cadherin, vimentin was detected using Western blotting after A172 and U87 cells were transferred with si-NC or si-circZNF652. **P < 0.01, ***P < 0.001.
Ablation suppressed GBM aggressiveness in a miR-486-5p-dependent manner. Specifically, the inhibitory effects of circZNF652 downregulation on cell viability and colony formation ability were reversed by miR-486-5p inhibitor (Figure 4f-k). Also, silencing of miR-486-5p abrogated the
regulating effects of circZNF652 silencing on cell migration (Figure 4(j, l)), invasion (Figure 4(I-m)) and EMT in GBM cells (Figure 4(n-q)).

**SERPINE1 was targeted by miR-486-5p in GBM cells**

To further investigate the potential target of miR-486-5p using StarBase (http://starbase.sysu.edu.cn/). We found that SERPINE1 was a predicted candidate target of miR-486-5p in human cells and tissues (Figure 5(a)). The interaction between miR-486-5p and SERPINE1 was measured by using luciferase activity reporter assay. As shown in Figure 5(b), the luciferase activity was inhibited by co-transfection of SERPINE1-wt and miR-486-5p mimic into 293 T cells compared to the mutant one. Furthermore, overexpression of miR-486-5p significantly suppressed both mRNA and protein levels of SERPINE1 in GBM cells (Figure 5(c-e)).

**CircZNF652 sponged miR-486-5p to modulate SERPINE1 expression in GBM cells**

Next, the correlations of circZNF652, miR-486-5p and SERPINE1 in GBM were analyzed. As shown in Figure 6(a, b), miR-486-5p was downregulated, while SERPINE1 was upregulated in GBM tissues compared to adjacent normal tissues. In addition, we noticed that high expression of miR-486-5p was associated with optimistic survival time, but high expression of SERPINE1 associated with poor survival time of GBM patients (Figure 6(c,d)). Spearman correlation analysis indicated that miR-486-5p was negatively relevant to both circZNF652 (R [2]=0.57, Figure 6(e)) and SERPINE1 (R [2]=0.22, Figure 6(f)), and the expression levels of circZNF652 and SERPINE1 showed positive correlations (R [2]=0.43, Figure 6(g)) in GBM tissues. Moreover, the mRNA and protein levels of SERPINE1 was inhibited by silencing circZNF652 in GBM cells (Figure 6(h-j)). Furthermore, we found the expression of circZNF652 was downregulated by overexpression of miR-486-5p, but the inhibitory effect of miR-486-5p was reversed by upregulated-SERPINE1 in GBM cells (Figure 6(k,l)).

**Upregulation of SERPINE1 reversed the inhibitory effects of miR-486-5p on GBM cell growth, migration, invasion, and EMT process**

Moreover, the rescue experiment was used to verify the correlation between miR-486-5p and SERPINE1 in the progression of GBM. As shown in Figure a-d, the cell viability and colony formation ability were inhibited by upregulation of miR-486-5p, and the inhibitory effect of upregulation of miR-486-5p was reversed by upregulated-SERPINE1. Also, the inhibitory effects of overexpression of miR-486-5p on cell migration, invasion, EMT process were abolished by upregulated-SERPINE1 (Figure 7(e-l)). Our finding suggested

Figure 5. SERPINE1 was targeted by miR-486-5p in GBM cells. (a) The predicted binding sites between SERPINE1 and miR-486-5p were speculated using StarBase. (b) The luciferase activity of SERPINE1-wt/mut co-transfected with NC mimic or miR-486-5p mimic into 293 T cells. (c-e) The mRNA and protein levels of SERPINE1 after A172 and U87 cells were transfected with NC mimic or miR-486-5p mimic. ***P < 0.001.
that overexpression of SERPINE1 reduced the inhibitory effects of miR-486-5p on cell growth, migration, invasion and EMT process.

**Knockdown of circZNF652 blocked xenograft tumor growth in vivo**

To further determine the effect of circZNF652 in vivo, the A172 cells stably transfected with si-NC or si-circZNF652 were injected into the dorsal flank of nude mice. As shown in Figure 8(a-c) and Figure S2, tumor formation and growth were suppressed by downregulated-ZNF652 in vivo. And the IHC staining results showed the percentages of Ki67-positive cells were decreased by downregulated-circZNF652 in mice tumor tissues (Figure 8(d,e)). Besides, the epithelial cell marker E-cadherin expression was increased, and the mesenchymal cell markers N-cadherin and vimentin were decreased by downregulated ZNF652 in vivo (Figure 8(f-i)).

**Discussion**

GBM is the most common malignant, high aggressive, rapid recurrent brain tumor, despite the advances in treatment [19], GBM patients also have a poor prognosis and short survival time [20]. Therefore, the novel and effective diagnostic and therapeutic molecular markers are urgent to be identified. CircRNAs are a class of conserved and closed circular non-coding RNAs without protein coding ability. CircRNAs function as miRNA spongers to inhibit miRNA binding with target mRNA [21,22]. CircRNAs usually generate from the assembly process of mature mRNA, and form a unique exon-exon junction and mostly distribute in cytoplasm [23]. Numerous circRNAs have been explored in GBM [24,25]. For example, hsa_circ_01844 acts as a tumor suppressor through inducing apoptosis and inhibiting cell proliferation and migration in GBM [26]. Moreover, circMMMP9 acts as an oncogene to promote multiforme cell tumorigenesis in GBM.
Thus, in the present study, we focused on exploring the role and effects of circZNF652 in GBM progression. We found circZNF652 was significantly increased in GBM patients and cell lines, and associated with advanced clinical stage and poor survival rate of patients. Previous study has demonstrated circZNF652 acts as an oncogene in HCC [12], our finding approved the function of circZNF652 that play as a tumor promoter.

Next, the underlying mechanisms by which circZNF652 functioned as an oncogene to aggravate cancer aggressiveness, and we verified that circZNF652 promotes cell proliferation, migration, invasion and EMT process by regulating the downstream miR-486-5p/SERPINE1 axis. Increasing evidences have revealed that miR-486-5p exerts dual function in tumors. For instance, Lin et al have demonstrated that...
LINC00857 promotes the progression and glycolysis by binding to miR-486-5p in ovarian cancer [28]. Besides, Zhang et al have proved that upregulation of miR-486-5p enhances gastric cancer cell chemo-sensitive to solasonine [29], and Zheng et al have demonstrated that miR-486-5p acts as an oncogene in endometrial carcinoma [30]. Here, we proved that miR-486-5p acted as a tumor suppressor in GBM, and miR-486-5p was confirmed to be sponged by circZNF652.

Moreover, SERPINE1 was identified as the target of miR-486-5p in our study. SERPINE1 is a fibrinolytic inhibitor that has been involved in several human tumor malignancies. For example, SERPINE1 has been indicated to be associated with PTX resistance of breast cancer [31], and LncRNA LINC00200 promotes the progression of gastric cancer by regulating miR-143-3p/SERPINE1 axis [32]. Li et al have reported that CEP72 induces bladder urothelial carcinoma cell aggressiveness by overexpression of SERPINE1 [33]. Moreover, SERPINE1 has been reported to promote GBM cell dispersal [34], and may be used as a predictor of prognosis and survival in gliomas [35]. Our finding is consistent with the above previous research results.

**Conclusions**

In conclusion, the present study for the first time identified that circZNF652 acted as an oncogene to accelerate GBM progression in vitro and in vivo, and the underlying mechanisms had also been elucidated. Mechanistically, circZNF652 sponged miR-486-5p to upregulate SERPINE1, resulting in the aggressiveness of GBM, which provided evidences to support that the novel circZNF652/miR-486-5p/SERPINE1 signaling cascade could be potentially used as diagnostic and prognostic biomarkers for GBM. However, more clinical data was still needed to validate our preliminary conclusions in our future work.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This study was financially supported by Shenzhen Sanming Project (No. SZSM201806067) and the Basic Research Project of People’s Hospital of Shenzhen Baoan District (No. SM2019002).
**Authors’ contributions**

Liang Liu and Shan Xiao designed this work, and conducted most of the investigations. Yan Wang, Zifeng Zhu, Yiyaocao, Sen Yang and Rongkang Mai provided technical support, and they collected, analyzed and visualized the data. Yong Zheng proofread the manuscript, and approved the final version of the manuscript for submission.

**ORCID**

Yong Zheng http://orcid.org/0000-0003-3398-589X

**References**

[1] Li L, Zhu X, Qian Y, et al. Chimeric Antigen Receptor T-Cell therapy in glioblastoma: current and future. Front Immunol. 2020;11:594271.

[2] Stupp R, Brada M, van Den Bent MJ, et al. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii93–101.

[3] Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18(11):1062–1071.

[4] Chistiakov DA, Chekhonin VP. Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. Exp Mol Pathol. 2018;105(2):166–174.

[5] Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2020;211:22–36.

[6] Guo Z, Xie M, Zou Y, et al. Circular RNA Hsa_circ_0006766 targets microRNA miR-4739 to regulate osteogenic differentiation of human bone marrow mesenchymal stem cells. Bioengineered. 2021;12(1):5679–5687.

[7] Gao C, Wen Y, Jiang F, et al. Circular RNA circ_0008274 upregulates granulin to promote the progression of hepatocellular carcinoma via sponging microRNA –140-3p. Bioengineered. 2021;12(1):1890–1901.

[8] Wang J, Huang K, Shi L, et al. CircPVT1 promoted the progression of breast cancer by regulating MiR-29a-3p-Mediated AGTR2-HIF-1a Pathway. Cancer Manag Res. 2020;12:11477–11490.

[9] Xu P, Wang, L, Xie, X, Hu, F, Yang, Q, Hu, R, Jiang, L, Ding, F, Mei, J, Liu, J, et al. Hsa_circ_0001869 promotes NSCLC progression via sponging miR-638 and enhancing FOSL2 expression. Aging (Albany NY). 2020;12(23):23836–23848.

[10] Wu Z, Zheng M, Zhang Y, et al. Hsa_circ_0043278 functions as competitive endogenous RNA to enhance glioblastoma multiforme progression by sponging miR-638. Aging (Albany NY). 2020;12(21):21114–21128.

[11] Lou J, Hao Y, Lin K, et al. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis. Mol Cancer. 2020;19(1):138.

[12] Guo J, Duan H, Li Y, et al. A novel circular RNA circ-ZNF652 promotes hepatocellular carcinoma metastasis through inducing snail-mediated epithelial-mesenchymal transition by sponging miR-203/miR-502-5p. Biochem Biophys Res Commun. 2019;513(4):812–819.

[13] Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 2016;98:12–23.

[14] Guo Y, Shi W, Fang R. miR-18a-5p promotes melanoma cell proliferation and inhibits apoptosis and autophagy by targeting EPHA7 signaling. Mol Med Rep. 2021;23(1):1.

[15] Wang H, Pan J, Yu L, et al. MicroRNA-16 inhibits glioblastoma growth in orthotopic model by targeting cyclin D1 and WIP1. Onco Targets Ther. 2020;13:10807–10816.

[16] Cui D, Wang K, Liu Y, et al. MicroRNA-623 inhibits epithelial-mesenchymal transition to attenuate glioma proliferation by targeting TRIM44. Onco Targets Ther. 2020;13:9291–9303.

[17] Salimian J, Baradaran B, Azimzadeh Jamalkandi S, et al. MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and down-regulation of metastatic genes. Urol Oncol. 2020;38(9):738.e9–738.e21.

[18] Li C, Zheng X, Li W, et al. Serum miR-486-5p as a diagnostic marker in cervical cancer: with investigation of potential mechanisms. BMC Cancer. 2018;18(1):61.

[19] Qi C, Lei L, Hu J, et al. Thrombospodin1-I is a prognostic biomarker and is correlated with tumor immune microenvironment in glioblastoma. Onco Lett. 2021;21(1):22.

[20] Liu W, Xu W, Li C, et al. Network pharmacological systems study of Huang-Lian-Tang in the treatment of glioblastoma multiforme. Onco Lett. 2021;21(1):18.

[21] Du WW, Zhang C, Yang W, et al. Identifying and Characterizing circRNA-Protein Interaction. Theranostics. 2017;7(17):4183–4191.

[22] Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12(4):381–388.

[23] Aufero S, van Den Hoogenhof MMG, Reckman YJ, et al. Cardiac circRNAs arise mainly from constitutive exons rather than alternatively spliced exons. Rna. 2018;24(6):815–827.

[24] Zhang Y, Lin X, Geng X, et al. Advances in circular RNAs and their role in glioma (Review). Int J Oncol. 2020;57(1):67–79.

[25] Wang R, Zhang S, Chen X, et al. CircNT5E Acts as a Sponge of miR-422a to promote glioblastoma tumorigenesis. Cancer Res. 2018;78(17):4812–4825.

[26] Zhou JX, Chen, KF, Hu, S, Dong, JR, Wang, HX, Su, X, Wang, YH, and Chu, JS. Up-regulation of circular RNA hsa_circ_01844 induces apoptosis and suppresses proliferation and migration of glioblastoma cells. Chin Med J (Engl). 2020;134(1):81–87.
[27] Wang R, Zhang S, Chen X, et al. Correction to: EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiforme cell tumorigenesis. Mol Cancer. 2020;19(1):153.
[28] Lin X, Feng D, Li P, et al. LncRNA LINC00857 regulates the progression and glycolysis in ovarian cancer by modulating the Hippo signaling pathway. Cancer Med. 2020;9(21):8122–8132.
[29] Zhang Y, Han G, Cao Y, et al. Solasonine inhibits gastric cancer proliferation and enhances chemosensitivity through microRNA-486-5p. Am J Transl Res. 2020;12(7):3522–3530.
[30] Zheng X, Xu K, Zhu L, et al. MiR-486-5p act as a biomarker in endometrial carcinoma: promotes cell proliferation, migration, invasion by targeting MARK1. Onco Targets Ther. 2020;13:4843–4853.
[31] Zhang Q, Lei L, Jing D. Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA. Oncol Rep. 2020;44(5):1875–1884.
[32] Yang JD, Ma L, Zhu Z. SERPINE1 as a cancer-promoting gene in gastric adenocarcinoma: facilitates tumour cell proliferation, migration, and invasion by regulating EMT. J Chemother. 2019;31(7–8):408–418.
[33] Li X, Dong P, Wei W, et al. Overexpression of CEP72 Promotes Bladder Urothelial Carcinoma Cell Aggressiveness via Epigenetic CREB-Mediated Induction of SERPINE1. Am J Pathol. 2019;189(6):1284–1297.
[34] Seker F, Cingoz A, Sur-Erdem İ, et al. Identification of SERPINE1 as a regulator of glioblastoma cell dispersal with transcriptome profiling. Cancers (Basel). 2019;11(11):11.
[35] Vachher M, Arora K, Burman A, et al. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas. J Cell Biochem. 2020;121(4):3010–3023.